

References

- Adigun R, Singh R. Tuberculosis. [Updated 2020 Jun 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441916/>
- Andersen, P., & Doherty, T. M. (2005). The success and failure of BCG—implications for a novel tuberculosis vaccine. *Nature Reviews Microbiology*, 3(8), 656-662.
- Arregui, S., Sanz, J., Marinova, D., Martín, C., & Moreno, Y. (2016). On the impact of masking and blocking hypotheses for measuring the efficacy of new tuberculosis vaccines. *PeerJ*, 4, e1513. <https://doi.org/10.1101/cshperspect.a017855/10.7717/peerj.1513>
- Arregui, S., Sanz, J., Marinova, D., Martín, C., & Moreno, Y. (2016). On the impact of masking and blocking hypotheses for measuring the efficacy of new tuberculosis vaccines. *PeerJ*, 4, e1513. <https://doi.org/10.1101/cshperspect.a017855/10.7717/peerj.1513>
- Carvalho, A., Cardoso, C., Martire, T. M., Migliori, G. B., & Sant'Anna, C. C. (2018). Epidemiological aspects, clinical manifestations, and prevention of pediatric tuberculosis from the perspective of the End TB Strategy. *Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisiologia*, 44(2), 134–144. <https://doi.org/10.1590/s1806-37562017000000461>
- Chae, H., & Shin, S. J. (2018). Importance of differential identification of Mycobacterium tuberculosis strains for understanding differences in their prevalence, treatment efficacy, and vaccine development. *Journal of Microbiology*, 56(5), 300-311.
- Delogu, G., Sali, M., & Fadda, G. (2013). The biology of mycobacterium tuberculosis infection. *Mediterranean journal of hematology and infectious diseases*, 5(1), e2013070. <https://doi.org/10.4084/MJHID.2013.070>
- Gupta, A., Saqib, M., Singh, B., Pal, L., Nishikanta, A., & Bhaskar, S. (2019). Mycobacterium indicus pranii Induced Memory T-Cells in Lung Airways Are Sentinels for Improved Protection Against M.tb Infection. *Frontiers in immunology*, 10, 2359. <https://doi.org/10.3389/fimmu.2019.02359>
- Hutanamon, T., & Diatmo, H. (2020, August 7). Tuberculosis Interview (Civil Society Organization Perspective) [Online interview].
- Ilievska-Poposka, B., Metodieva, M., Zakoška, M., Vragoterova, C., & Trajkov, D. (2018). Latent Tuberculosis Infection - Diagnosis and Treatment. *Open access Macedonian journal of medical sciences*, 6(4), 651–655. <https://doi.org/10.3889/oamjms.2018.161>
- Ji, Z., Jian, M., Chen, T., Luo, L., Li, L., Dai, X., Bai, R., Ding, Z., Bi, Y., Wen, S., Zhou, G., Abi, M. E., Liu, A., & Bao, F. (2019). Immunogenicity and Safety of the M72/AS01E Candidate Vaccine Against Tuberculosis: A Meta-Analysis. *Frontiers in immunology*, 10, 2089. <https://doi.org/10.3389/fimmu.2019.02089>
- Katoch, K., Singh, P., Adhikari, T., Benara, S. K., Singh, H. B., Chauhan, D. S., ... & Katoch, V. M. (2008). Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. *Vaccine*, 26(9), 1228-1234.
- Kebijakan Kesehatan Indonesia. (2017, March 24). Setiap Tahun Pemerintah Kucurkan Dana 400 Miliar untuk Penanggulangan TB. Retrieved February 05, 2021, from <https://kebijakankesehatanindonesia.net/25-berita/berita/3237-setiap-tahun-pemerintah-kucurkan-dana-400-miliar-untuk-penanggulangan-tb#:~:text=24%20Mar2017-,Setiap%20Tahun%20Pemerintah%20Kucurkan%20Dana%20400%20Miliar%20untuk%20Penanggulangan%20TB,TB%20baru%20ditemukan%20setiap%20tahunnya.>

Kementerian Kesehatan Republik Indonesia. (2016). PERATURAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR 67 TAHUN 2016 TENTANG PENANGGULANGAN TUBERKULOSIS. Retrieved March 16, 2016, from http://hukor.kemkes.go.id/uploads/produk_hukum/PMK_No._67_ttg_Penanggulangan_Tuberkulosis_.pdf

Li, J., Zhan, L., & Qin, C. (2021). The double-sided effects of *Mycobacterium Bovis* bacillus Calmette-Guérin vaccine. *NPJ vaccines*, 6(1), 14. <https://doi.org/10.1038/s41541-020-00278-0>

Luabeya, A. K. K., Kagina, B. M., Tameris, M. D., Geldenhuis, H., Hoff, S. T., Shi, Z., ... & H56-032 Trial Study Group. (2015). First-in-human trial of the post-exposure tuberculosis vaccine H56: IC31 in *Mycobacterium tuberculosis* infected and non-infected healthy adults. *Vaccine*, 33(33), 4130-4140.

Marais, B. J., & Schaaf, H. S. (2014). Tuberculosis in children. *Cold Spring Harbor perspectives in medicine*, 4(9), a017855. <https://doi.org/10.1101/cshperspect.a017855>

Martin, C., Aguiló, N., Marinova, D., & Gonzalo-Asensio, J. (2020). Update on TB vaccine pipeline. *Applied Sciences*, 10(7), 2632.

Masonou, T., Hokey, D. A., Lahey, T., Halliday, A., Berrocal-Almanza, L. C., Wieland-Alter, W. F., Arbeit, R. D., Lalvani, A., & von Reyn, C. F. (2019). CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial. *PloS one*, 14(5), e0217091. <https://doi.org/10.1371/journal.pone.0217091>

Munseri, P., Said, J., Amour, M., Magohe, A., Matee, M., Rees, C. A., ... & von Reyn, C. F. (2020). DAR-901 vaccine for the prevention of infection with *Mycobacterium tuberculosis* among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial. *Vaccine*, 38(46), 7239-7245.

Narasimhan, P., Wood, J., Macintyre, C. R., & Mathai, D. (2013). Risk factors for tuberculosis. *Pulmonary medicine*, 2013, 828939. <https://doi.org/10.1155/2013/828939>

Nieuwenhuizen, N. E., Kulkarni, P. S., Shaligram, U., Cotton, M. F., Rentsch, C. A., Eisele, B., Grode, L., & Kaufmann, S. (2017). The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing. *Frontiers in immunology*, 8, 1147. <https://doi.org/10.3389/fimmu.2017.01147>

O'Brien, M. E., Saini, A., Smith, I. E., Webb, A., Gregory, K., Mendes, R., Ryan, C., Priest, K., Bromelow, K. V., Palmer, R. D., Tuckwell, N., Kennard, D. A., & Souberbielle, B. E. (2000). A randomized phase II study of SRL172 (*Mycobacterium vaccae*) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. *British journal of cancer*, 83(7), 853–857. <https://doi.org/10.1054/bjoc.2000.1401>

Patel, P. M., Sim, S., O'Donnell, D. O., Protheroe, A., Beirne, D., Stanley, A., ... & Selby, P. J. (2008). An evaluation of a preparation of *Mycobacterium vaccae* (SRL172) as an immunotherapeutic agent in renal cancer. *European Journal of Cancer*, 44(2), 216-223.

Pollard, A. J., & Bijker, E. M. (2021). A guide to vaccinology: from basic principles to new developments. *Nature reviews. Immunology*, 21(2), 83–100. <https://doi.org/10.1038/s41577-020-00479-7>

Prabowo, S. A., Painter, H., Zelmer, A., Smith, S. G., Seifert, K., Amat, M., Cardona, P. J., & Fletcher, H. A. (2019). RUTI Vaccination Enhances Inhibition of Mycobacterial Growth ex vivo and Induces a

Shift of Monocyte Phenotype in Mice. *Frontiers in immunology*, 10, 894. <https://doi.org/10.3389/fimmu.2019.00894>

Pranita, E. (2020, February 1). TBC Bisa Diobati dan Gratis, Ahli Tegaskan Pasien Jangan Mangkir Berobat (1050731822 802520464 S. W. Wibawa, Ed.). Kompas. Retrieved November 13, 2020, from <https://sains.kompas.com/read/2020/02/01/170300023/tbc-bisa-diobati-dan-gratis-ahli-tegas-kan-pasien-jangan-mangkir-berobat>

Rakshit, S., Ahmed, A., Adiga, V., Sundararaj, B. K., Sahoo, P. N., Kenneth, J., D'Souza, G., Bonam, W., Johnson, C., Franken, K. L., Ottenhoff, T. H., Finak, G., Gottardo, R., Stuart, K. D., De Rosa, S. C., McElrath, M. J., & Vyakarnam, A. (2019). BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults. *JCI insight*, 4(24), e130540. <https://doi.org/10.1172/jci.insight.130540>

Reksoprodjo, M. (2020, August 14). Tuberculosis Interview (Civil Society Organization Perspective) Part 2 [Personal interview].

Reksoprodjo, M. (2020, August 5). Tuberculosis Interview (Civil Society Organization Perspective) Part 1 [Personal interview].

Suliman, S., Luabeya, A. K. K., Geldenhuys, H., Tameris, M., Hoff, S. T., Shi, Z., ... & Hatherill, M. (2019). Dose optimization of H56: IC31 vaccine for tuberculosis-endemic populations. A double-blind, placebo-controlled, dose-selection trial. *American Journal of Respiratory and Critical Care Medicine*, 199(2), 220-231.

TBCIndonesia. (2020). Situasi TBC di Indonesia. Retrieved November 6, 2020, from <https://tbindonesia.or.id/informasi/tentang-tbc/situasi-tbc-di-indonesia-2/>

TBCIndonesia. (2020). TB Anak. Retrieved March 17, 2020, from <https://tbindonesia.or.id/pustaka/pedoman/tb-anak/>

WHO. (2020, September 3). WHO's Product Development for Vaccines Development Committee Virtual session 6. Retrieved February 03, 2021, from https://www.who.int/immunization/research/meetings_workshops/PDVAC_TB_virtual-session-3-Sept-2020_Presentations.pdf?ua=1

WHO. (2020). Global tuberculosis report 2020. WHO. Retrieved November 10, 2020, from <https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf?ua=1>

Zuniga, J., Torres-García, D., Santos-Mendoza, T., Rodriguez-Reyna, T. S., Granados, J., & Yunis, E. J. (2012). Cellular and humoral mechanisms involved in the control of tuberculosis. *Clinical and Developmental Immunology*, 2012.

Zhang, L., Ru, H. W., Chen, F. Z., Jin, C. Y., Sun, R. F., Fan, X. Y., ... & Liu, J. (2016). Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms. *Molecular Therapy*, 24(2), 398-405.